Skip to content

US · SERA · MEDICAL - DIAGNOSTICS & RESEARCH

Sera Prognostics, Inc. (SERA) intrinsic value and stock valuation

$1.81as of 2026-11-21 · Mkt cap 76.38M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sera Prognostics, Inc. DCF and intrinsic value

InvestorsCraft values SERA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SERA’s statements →

Sera Prognostics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Salt Lake City, UT 84109 sera.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$80K+21.7% 5y CAGRd
20192025
Net income
-$-31.93M
20192025
Free cash flow
-$-26.35M
20192025
Total equity
$75.4M+91.3% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$80K$80K$310K$270K$80K
Operating income-$-36.5M-$-36.63M-$-39.82M-$-45.65M-$-35.4M
Net income-$-31.93M-$-32.9M-$-36.24M-$-44.19M-$-35.01M
EPSd-$-669.95K-$-992.16K-$-1.16M-$-1.43M-$-1.14M
Operating cash flow-$-25.62M-$-14.19M-$-27.19M-$-34.61M-$-31.64M
Capital expenditure-$-730K-$-1.1M-$-130K-$-790K-$-1.3M
Free cash flow-$-26.35M-$-15.29M-$-27.32M-$-35.4M-$-32.94M
Total assets$101.9M$72.6M$95.4M$116.3M$147M
Total debt$2.34M$840K$1.86M$2.83M$130K
Net debt-$-1.6M-$-3.2M-$-2.02M-$-27.05M-$-58.8M
Total equity$75.4M$47.8M$70.2M$98.9M$138.6M
Cash and short-term investments$39.2M$46.2M$49.1M$82.7M$105.1M
Income statement
20252024202320222021
Revenue$80K$80K$310K$270K$80K
Cost of revenue$160K$80K$210K$190K$40K
Gross profit-$-80K-$-10K$100K$70K$40K
Research and development expenses$13.2M$14.7M$15.2M$14.2M$11M
Selling, general and administrative expenses$23.3M$21.9M$24.7M$31.5M$24.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$36.4M$36.6M$39.9M$45.7M$35.4M
Cost and expenses$36.6M$36.7M$40.1M$45.9M$35.5M
Interest income$4.58M$2.75M$1.64M$460K$140K
Interest expense$10K$30K$60K$60K$750K
Depreciation and amortization$940K$830K$900K$760K$660K
Ebitda-$-30.98M-$-32.04M-$-35.29M-$-43.37M-$-33.6M
Operating income-$-36.5M-$-36.63M-$-39.82M-$-45.65M-$-35.4M
Total other income/expenses, net$4.58M$3.74M$3.58M$1.47M$390K
Income before tax-$-31.93M-$-32.9M-$-36.24M-$-44.19M-$-35.01M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-31.93M-$-32.9M-$-36.24M-$-44.19M-$-35.01M
Weighted average shares outstanding$47.7M$33.2M$31.2M$30.9M$30.8M
Weighted average diluted shares outstanding$47.7M$33.2M$31.2M$30.9M$30.8M
Balance sheet
20252024202320222021
Cash and short-term investments$39.2M$46.2M$49.1M$82.7M$105.1M
Net receivables$10K$30K$11.5M$6.11M$3.14M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$40.8M$47.6M$61.3M$90.1M$110.3M
Property, plant and equipment, net$3.55M$1.85M$3.18M$3.06M$1.77M
Goodwill and intangible assets$910K$1.03M$0.00$0.00$0.00
Long-term investments$56.6M$22M$30.8M$21.3M$34.9M
Total non-current assets$61.2M$25M$34.1M$26.2M$36.8M
Total assets$101.9M$72.6M$95.4M$116.3M$147M
Accounts payable$860K$1.97M$1.05M$1.55M$1.2M
Short-term debt$0.00$840K$1.02M$980K$70K
Deferred revenue$20.3M$20.2M$20.2M$9.08M$3.12M
Total current liabilities$24.2M$24.8M$24.4M$15.5M$8.41M
Long-term debt$2.34M$0.00$840K$1.85M$50K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.34M$0.00$840K$1.85M$50K
Capital lease obligations$2.34M$840K$1.86M$2.83M$130K
Total liabilities$26.5M$24.8M$25.3M$17.4M$8.46M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-311.72M-$-279.79M-$-246.9M-$-210.65M-$-166.47M
Accumulated other comprehensive income (loss)$260K$60K-$-10K-$-980K-$-180K
Total equity$75.4M$47.8M$70.2M$98.9M$138.6M
Total investments$91.8M$64.2M$76M$74.2M$81M
Total debt$2.34M$840K$1.86M$2.83M$130K
Net debt-$-1.6M-$-3.2M-$-2.02M-$-27.05M-$-58.8M
Cash flow statement
20252024202320222021
Net income-$-31.93M-$-32.9M-$-36.24M-$-44.19M-$-35.01M
Depreciation and amortization$940K$830K$900K$760K$660K
Stock-based compensation$5.11M$7.01M$5.27M$5.05M$3.13M
Change in working capital-$-550K$11.3M$3.52M$3.55M-$-40K
Accounts receivable$20K$11.4M-$-5.36M-$-2.97M-$-3.14M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.01M$460K-$-440K$350K$600K
Net cash provided by operating activities-$-25.62M-$-14.19M-$-27.19M-$-34.61M-$-31.64M
Investments in property, plant and equipment-$-730K-$-60K-$-130K-$-790K-$-1.3M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-28.5M$11.7M$440K$5.55M-$-82.56M
Common stock issued$54.2M$0.00$0.00$0.00$66.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$54M$2.61M$750K$10K$159.6M
Net change in cash-$-100K$160K-$-26M-$-29.05M$45.4M
Cash at end of period$3.94M$4.04M$3.88M$29.9M$58.9M
Operating cash flow-$-25.62M-$-14.19M-$-27.19M-$-34.61M-$-31.64M
Capital expenditure-$-730K-$-1.1M-$-130K-$-790K-$-1.3M
Free cash flow-$-26.35M-$-15.29M-$-27.32M-$-35.4M-$-32.94M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sera Prognostics, Inc.

        Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

        CEO
        Zhenya Lindgardt
        Employees
        63
        Beta
        0.97

        Explore

        Frequently asked questions

        What is the intrinsic value of Sera Prognostics, Inc. (SERA)?

        Sera Prognostics, Inc. (SERA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SERA undervalued?

        SERA trades at a price of $1.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.